It seems likely that the higher risk of ICANS after CD19-targeted therapies reflects their capacity for robust T cell activation compared to T cell therapies targeting other antigens expressed on different tumours, possibly related to the higher accessibility to CD19 tumour cells, or their level of antigen expression [11]. This evidence concerns the gene CD19 and neoplasm.